Replies to post #106022 on Biotech Values

[biopearl]

In the interim found the RELY study of dabigatran in acute coronary syndromes. Looks like an excess of MI in the treatment group, looks like we don't have to worry yet. Dag, however will replace coumdin in Afib for sure. bp